Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

被引：72

作者：

Wislez, Marie ^{[1
]}

Mazieres, Julien ^{[2
]}

Lavole, Armelle ^{[3
]}

Zalcman, Gerard ^{[4
]}

Carre, Olivier ^{[5
]}

Egenod, Thomas ^{[6
]}

Caliandro, Raffaele ^{[7
]}

Dubos-Arvis, Catherine ^{[8
]}

Jeannin, Gaelle ^{[9
]}

Molinier, Olivier ^{[10
]}

Massiani, Marie-Ange ^{[11
]}

Langlais, Alexandra ^{[12
]}

Morin, Franck ^{[13
]}

Barthes, Francoise Le Pimpec ^{[14
]}

Brouchet, Laurent ^{[15
]}

Assouad, Jalal ^{[16
]}

Milleron, Bernard ^{[13
]}

Damotte, Diane ^{[17
]}

Antoine, Martine ^{[18
]}

Westeel, Virginie ^{[19
]}

机构：

[1] Univ Paris Cite, Pneumol, Hop Cochin, Assistance Publ Hop Paris APHP, Paris, France

[2] CHU Toulouse, Pneumol, Hop Larrey, Toulouse, France

[3] Univ Paris Cite, Hop Tenon, Pneumol, Paris, France

[4] Univ Paris Cite, Hop Bichat, Assistance Publ Hop Paris APHP, Thorac Oncol, Paris, France

[5] Clin Europe, Pneumol, Amiens, France

[6] Hop Dupuytren, Thorac Oncol, Limoges, France

[7] Inst Mutualiste Montsouris, Pneumol, Paris, France

[8] Ctr Francois Baclesse, Pneumol, Caen, France

[9] Hop Gabriel Montpied, Thorac Oncol, Clermont Ferrand, France

[10] Ctr Hosp Mans, Pneumol, Le Mans, France

[11] Hop Rene Huguenin, Med Oncol, Inst Curie, St Cloud, France

[12] French Cooperat Thorac Intergrp, Biostat, Paris, France

[13] French Cooperat Thorac Intergrp, Clin Res Unit, Paris, France

[14] Hop Europeen Georges Pompidou, Thorac Surg, Paris, France

[15] CHU Toulouse, Thorac Oncol, Hop Larrey, Toulouse, France

[16] Univ Paris Cite, Hop Tenon, Assistance Publ Hop Paris APHP, Thorac Surg, Paris, France

[17] Univ Paris Cite, Hop Cochin, Assistance Publ Hop Paris APHP, Pathol, Paris, France

[18] Univ Paris Cite, Hop Tenon, Pathol, Paris, France

[19] Hop Jean Minjoz, Pneumol, Besancon, France

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 10期

关键词：

Immunotherapy; Lung Neoplasms; Biomarkers; Tumor; Programmed Cell Death 1 Receptor; SINGLE-ARM; OPEN-LABEL; ATEZOLIZUMAB; CHEMOTHERAPY;

D O I：

10.1136/jitc-2022-005636

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). Methods In a multicenter, single-arm, phase II trial, patients with IB (>= 4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: <= 10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131). Results Forty-six patients were eligible (median age 60.9 years); 67% were male, 98% were smokers, and 41% had squamous cell carcinoma. Regarding tumor response, 9% had a partial response, 78% had stable disease, and 13% had progressive disease. Among the operated patients (n=43), 41 achieved complete resection (89%, 95% CI 80.1% to 98.1%)), and eight achieved MPR (19%). The 12-month median OS and DFS rates were 89% (95% CI 75.8% to 95.3%) and 78% (95% CI 63.4% to 87.7%), respectively (n=46). The median follow-up was 28.4 months (12.8-41.1). All patients in whom MPR was achieved were disease-free at 12 months compared to only 11% of those with >10% residual tumor cells (p=0.04). No durvalumab-related serious or grade 3-5 events were reported. The unexpected 90-day postoperative mortality of four patients led to premature study termination. None of these four deaths was considered secondary to direct durvalumab-related toxicity. Conclusions Neoadjuvant durvalumab given as monotherapy was associated with an 89% complete resection rate and an MPR of 19%. Despite an unexpectedly high rate of postoperative deaths, which prevented us from completing the trial, we were able to show a significant association between MPR and DFS.

引用

页数：8

共 18 条

[11]

Lee J, 2021, J THORAC ONCOL, V16, pS59

[12] Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease [J].

Liu, Jing ;

Blake, Stephen J. ;

Yong, Michelle C. R. ;

Harjunpaa, Heidi ;

Ngiow, Shin Foong ;

Takeda, Kazuyoshi ;

Young, Arabella ;

O'Donnell, Jake S. ;

Allen, Stacey ;

Smyth, Mark J. ;

Teng, Michele W. L. .

CANCER DISCOVERY, 2016, 6 (12) :1382-1399

[13] VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study [J].

Paz-Ares, L. ;

O'Brien, M. E. R. ;

Mauer, M. ;

Dafni, U. ;

Oselin, K. ;

Havel, L. ;

Gonzalez, E. Esteban ;

Isla, D. ;

Martinez-Marti, A. ;

Faehling, M. ;

Tsuboi, M. ;

Lee, J-s. ;

Nakagawa, K. ;

Yang, J. ;

Keller, S. M. ;

Jha, N. ;

Marreaud, S. I. ;

Stahel, R. A. ;

Peters, S. ;

Besse, B. .

ANNALS OF ONCOLOGY, 2022, 33 (04) :451-453

[14] Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial [J].

Provencio, Mariano ;

Nadal, Ernest ;

Insa, Amelia ;

Rosario Garcia-Campelo, Maria ;

Casal-Rubio, Joaquin ;

Domine, Manuel ;

Majem, Margarita ;

Rodriguez-Abreu, Delvys ;

Martinez-Marti, Alex ;

De Castro Carpeno, Javier ;

Cobo, Manuel ;

Lopez Vivanco, Guillermo ;

Del Barco, Edel ;

Bernabe Caro, Reyes ;

Vinolas, Nuria ;

Barneto Aranda, Isidoro ;

Viteri, Santiago ;

Pereira, Eva ;

Royuela, Ana ;

Casarrubios, Marta ;

Salas Anton, Clara ;

Parra, Edwin R. ;

Wistuba, Ignacio ;

Calvo, Virginia ;

Laza-Briviesca, Raquel ;

Romero, Atocha ;

Massuti, Bartomeu ;

Cruz-Bermudez, Alberto .

LANCET ONCOLOGY, 2020, 21 (11) :1413-1422

[15] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer [J].

Reuss, Joshua E. ;

Anagnostou, Valsamo ;

Cottrell, Tricia R. ;

Smith, Kellie N. ;

Verde, Franco ;

Zahurak, Marianna ;

Lanis, Mara ;

Murray, Joseph C. ;

Chan, Hok Yee ;

McCarthy, Caroline ;

Wang, Daphne ;

White, James R. ;

Yang, Stephen ;

Battafarano, Richard ;

Broderick, Stephen ;

Bush, Errol ;

Brock, Malcolm ;

Ha, Jinny ;

Jones, David ;

Merghoub, Taha ;

Taube, Janis ;

Velculescu, Victor E. ;

Rosner, Gary ;

Illei, Peter ;

Pardoll, Drew M. ;

Topalian, Suzanne ;

Naidoo, Jarushka ;

Levy, Ben ;

Hellmann, Matthew ;

Brahmer, Julie R. ;

Chaft, Jamie E. ;

Forde, Patrick M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[16] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial [J].

Rothschild, Sacha, I ;

Zippelius, Alfred ;

Eboulet, Eric, I ;

Prince, Spasenija Savic ;

Betticher, Daniel ;

Bettini, Adrienne ;

Frueh, Martin ;

Joerger, Markus ;

Lardinois, Didier ;

Gelpke, Hans ;

Mauti, Laetitia A. ;

Britschgi, Christian ;

Weder, Walter ;

Peters, Solange ;

Mark, Michael ;

Cathomas, Richard ;

Ochsenbein, Adrian F. ;

Janthur, Wolf-Dieter ;

Waibel, Christine ;

Mach, Nicolas ;

Froesch, Patrizia ;

Buess, Martin ;

Bohanes, Pierre ;

Godar, Gilles ;

Rusterholz, Corinne ;

Gonzalez, Michel ;

Pless, Miklos .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) :2872-+

[17] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial [J].

Shu, Catherine A. ;

Gainor, Justin F. ;

Awad, Mark M. ;

Chiuzan, Codruta ;

Grigg, Claud M. ;

Pabani, Aliyah ;

Garofano, Robert F. ;

Stoopler, Mark B. ;

Cheng, Simon K. ;

White, Abby ;

Lanuti, Michael ;

D'Ovidio, Frank ;

Bacchetta, Matthew ;

Sonett, Joshua R. ;

Saqi, Anjali ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2020, 21 (06) :786-795

[18] IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). [J].

Wakelee, Heather A. ;

Altorki, Nasser K. ;

Zhou, Caicun ;

Csoszi, Tibor ;

Vynnychenko, Ihor O. ;

Goloborodko, Oleksandr ;

Luft, Alexander ;

Akopov, Andrey ;

Martinez-Marti, Alex ;

Kenmotsu, Hirotsugu ;

Chen, Yuh-Min ;

Chella, Antonio ;

Sugawara, Shunichi ;

Gitlitz, Barbara J. ;

Bennett, Elizabeth ;

Wu, Fan ;

Yi, Jing ;

Deng, Yu ;

McCleland, Mark ;

Felip, Enriqueta .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 →